Review

        Next >  
Regulated cell death in organ transplantation: recent developments and mechanistic overview
Qian Chen1,2 , Jiashi Sun1 , Shifan Zhu1 , Minghui Wu1 , Hakjun Lee1,2 , Azeem Alam2 , Moradi Kimia1 , Enqiang Chang2 , Hailin Zhao2 , Yue Jin1,* , Daqing Ma1,2,*
1Department of Anaesthesiology, Perioperative and System Medicine Laboratory, Children’s Hospital, National Clinical Research Center for Child Health, Zhejiang University School of Medicine, Hangzhou 310003, China
2Division of Anaesthetics, Pain Medicine and Intensive Care, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Chelsea & Westminster Hospital, London SW7 2AZ, UK
*Correspondence to:Daqing Ma , Email:d.ma@imperial.ac.uk, daqingma91@zju.edu.cn Yue Jin , Email:yue_jin@zju.edu.cn
J Mol Cell Biol, Volume 17, Issue 7, July 2025, mjaf034,  https://doi.org/10.1093/jmcb/mjaf034
Keyword: organ transplantation, ischaemia–reperfusion, donation after circulatory death, donation after brain death, regulated cell death

Organ transplantation is a definitive therapeutic option for patients with end-stage organ dysfunction and failure. Ischaemia–reperfusion (IR) injury is one of the leading causes of low graft utilization as it significantly increases the risk of primary graft dysfunction and acute rejection following transplantation. This risk is particularly high for organs obtained from donation after circulatory death (DCD) when compared with the organs from donation after brain death (DBD). IR injury exacerbates tissue damage via various mechanisms including the induction of regulated cell death. Regulated cell death and its consequences play critical roles in determining graft survival and function, thereby influencing the overall success of the transplant. Understanding the mechanisms underlying regulated cell death in IR injury is essential for developing therapeutic strategies to minimize tissue damage and improve clinical outcomes in organ transplantation. This review mainly discusses different types of regulated cell death and underlying mechanisms towards preventive cell death strategies in DBD and DCD organ transplantation in preclinical settings.